6.67
Rocket Pharmaceuticals Inc stock is traded at $6.67, with a volume of 6.51M.
It is down -12.12% in the last 24 hours and down -29.42% over the past month.
See More
Previous Close:
$7.59
Open:
$7.21
24h Volume:
6.51M
Relative Volume:
4.24
Market Cap:
$930.88M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-2.4255
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
-23.60%
1M Performance:
-29.42%
6M Performance:
-63.89%
1Y Performance:
-75.24%
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RCKT
Rocket Pharmaceuticals Inc
|
6.67 | 930.88M | 0 | -258.08M | -202.32M | -2.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
Dec-30-24 | Initiated | Wedbush | Outperform |
Dec-18-24 | Initiated | Jefferies | Buy |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Apr-02-24 | Initiated | Goldman | Neutral |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Feb-01-23 | Initiated | Morgan Stanley | Overweight |
Nov-08-22 | Initiated | Canaccord Genuity | Buy |
Nov-01-22 | Initiated | BTIG Research | Buy |
Jul-08-22 | Initiated | Raymond James | Outperform |
Oct-20-21 | Resumed | Cowen | Outperform |
Mar-02-21 | Initiated | Stifel | Buy |
Feb-18-21 | Initiated | Needham | Buy |
Dec-16-20 | Initiated | UBS | Buy |
Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
Jul-02-20 | Initiated | JP Morgan | Overweight |
Jun-25-20 | Resumed | BofA/Merrill | Buy |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
Sep-26-19 | Initiated | Piper Jaffray | Overweight |
Apr-23-19 | Initiated | Robert W. Baird | Outperform |
Mar-15-19 | Initiated | BofA/Merrill | Buy |
Feb-05-19 | Initiated | Oppenheimer | Outperform |
Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowHere's Why - MarketBeat
Swiss National Bank Has $1.93 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - Yahoo Finance
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
PNC Financial Services Group Inc. Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Bank of New York Mellon Corp Buys 9,949 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Fanconi Anemia Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
What technical indicators reveal about RCKT stock - US Post News
Steward Partners Investment Advisory LLC Has $84,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Arizona State Retirement System - Defense World
BMO Capital Markets Begins Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
(RCKT) Investment Analysis and Advice - news.stocktradersdaily.com
BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target - Marketscreener.com
BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq
Rocket Pharmaceuticals: A Buy Rating for Its Pioneering Gene Therapy Approach and Promising Pipeline - TipRanks
BMO Capital sets $50 target for Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.25 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Insider Monkey
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $15.00 by Analysts at The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $52.00 at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $36.00 at Canaccord Genuity Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade - Defense World
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s Stock Adds 0.53%, Making It A Good Investment - Stocks Register
Scotiabank raises Rocket Pharmaceuticals target to $52 - Investing.com
What is William Blair’s Estimate for RCKT Q1 Earnings? - Defense World
Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World
What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia
Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN
Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target - TipRanks
Rocket Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Rocket Pharmaceuticals Rings the Opening Bell - Nasdaq
Cantor Fitzgerald cuts Rocket Pharmaceuticals target to $50 By Investing.com - Investing.com Canada
Rocket Pharmaceuticals price target lowered to $54 from $62 at Chardan - TipRanks
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):